Nicole Lasecki
Nurse Practitioner · Miami, FLNPI 1942380084
Payments from drug & device makers
Across 310 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Astellas Pharma US Inc$866
- Sumitomo Pharma America, Inc.$624
- Boston Scientific$407
- AbbVie$342
- Tolmar Pharmaceuticals, Inc.$258
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,89794%
- Education$3026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 148 | $1,628 |
| Astellas Pharma US Inc | 45 | $866 |
| Sumitomo Pharma America, Inc. | 28 | $624 |
| Boston Scientific | 14 | $407 |
| AbbVie | 15 | $342 |
| Tolmar Pharmaceuticals, Inc. | 12 | $258 |
| Verity Pharmaceuticals Inc. | 9 | $192 |
| Pfizer | 8 | $162 |
| Blue Earth Diagnostics | 4 | $100 |
| Tolmar, Inc. | 4 | $97 |
| Myovant Sciences Inc. | 3 | $75 |
| Teleflex LLC | 2 | $69 |
| Urovant Sciences Inc | 3 | $59 |
| Endo Pharmaceuticals Inc. | 3 | $56 |
| Novartis | 2 | $50 |
| Merck | 2 | $39 |
| Axonics, Inc. | 2 | $39 |
| Angiodynamics, Inc. | 1 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| Bayer | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Endo USA, Inc. | 1 | $20 |
How this compares
$5,199 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 20 | $307,870 |
| MyrbetriqMirabegron | 138 | $117,145 |
| GemtesaVibegron | 110 | $114,708 |
| Tamsulosin Hcl | 933 | $9,517 |
| Tadalafil | 65 | $6,386 |
| CefuroximeCefuroxime Axetil | 310 | $3,753 |
| Bicalutamide | 127 | $3,715 |
| Finasteride | 310 | $3,395 |
| Estradiol | 49 | $2,679 |
| Sildenafil Citrate | 284 | $1,893 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 44 | $1,203 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $933 |
| Testosterone Cypionate | 29 | $864 |
| Doxycycline Hyclate | 114 | $662 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,628 | $307,87020 claims |
| Astellas Pharma US IncMyrbetriq | $866 | $117,145138 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $624 | $114,708110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Miami
- Margarita FernandezMiami$311K
- Maya BloombergMiami$202K
- Haydee KapinMiami$97K
- Terri PollackMiami$59K
- Amber FederizoMiami$39K
- Patricia Novoa-VogtMiami$35K
- Moriane JosephMiami$23K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.